Initiation of clinical imaging study
Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV.STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals AB (publ) (“Annexin”) announces that its collaborators have received approval from the Dutch regulatory authority to start an innovative clinical molecular imaging study of Annexin’s fluorescent labelled candidate drug ANXV in patients with venous occlusion in the retina (RVO). The trial is managed by TRACER, a CRO specialized in fast-track clinical imaging trials, and is being